Agios Pharmaceuticals
AGIO
151 hedge funds and large institutions have $2.22B invested in Agios Pharmaceuticals in 2015 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 60 increasing their positions, 46 reducing their positions, and 34 closing their positions.
30% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 46
7% less funds holding
Funds holding: 162 → 151 (-11)
24% less call options, than puts
Call options by funds: $16.4M | Put options by funds: $21.6M
29% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 34
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
34% less capital invested
Capital invested by funds: $3.35B → $2.22B (-$1.13B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$63.7M |
| 2 |
First Trust Advisors
Wheaton,
Illinois
|
+$53.2M |
| 3 |
Capital International Investors
Los Angeles,
California
|
+$22M |
| 4 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$19.8M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$18.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CGT
Capital Guardian Trust
Los Angeles,
California
|
-$30.4M |
| 2 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
-$20.1M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$16.8M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$15.9M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$15.4M |
AGIO Hedge Fund Activity: Q3 2015 in Review
151 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q3 2015, worth a combined $2.22B — down 34% from $3.35B a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of AGIO and 24 opened new positions — a net loss of 10 holders — while 46 trimmed existing stakes and 60 added.
The largest buyer was Wellington Management Group, adding an estimated $63.7M. The largest seller was Capital Guardian Trust, cutting an estimated $30.4M.
- 151 institutional investors held Agios Pharmaceuticals (AGIO) as of Q3 2015, down from 162 in Q2 2015.
- Funds reported $2.22B of Agios Pharmaceuticals stock for Q3 2015, down 34% quarter-over-quarter.
- 24 funds opened new Agios Pharmaceuticals positions in Q3 2015 and 34 closed out, a net change of -10 holders.
- The largest Agios Pharmaceuticals buyer in Q3 2015 was Wellington Management Group, an estimated $63.7M added.
- The largest Agios Pharmaceuticals seller in Q3 2015 was Capital Guardian Trust, an estimated $30.4M sold.
Based on aggregated 13F filings for Q3 2015.